Insomnia and the Risk of Atrial Fibrillation: A Nationwide, Real-World Cohort Study

Atrial FibrillationHeart FailureThrombosis and Stroke

Heart Failure and Stroke Risk in Atrial Fibrillation: Temporal Trends From a Nationwide Cohort Study

J Am Heart Assoc

Jalli E, Langén V, Jaakkola J, Airaksinen KEJ, Halminen O, Putaala J, Mustonen P, Haukka J, Hartikainen J, Linna M, Lehto M, Teppo K

doi: 10.1161/JAHA.124.040758

Atrial Fibrillation

Atrial fibrillation recurrence and outcomes in patients with hypertrophic cardiomyopathy: Insights from a nationwide real-world cohort

Heart Rhythm

Aglan A, Fath AR, Silver JS, Harnish P, Hook B, Maron MS, Rowin EJ

doi: 10.1016/j.hrthm.2026.03.1906

Atrial Fibrillation

Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation

J Am Heart Assoc

Lip GYH, Cheng D, Jiang J, Gao C, Subash R, Vodicka E, Dubey A, Sharma PP, Vettumthara Unnikrishnan A, Mathivanan K, Deitelzweig S

doi: 10.1161/JAHA.125.044113

Cardiovascular Risk and Diseases

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Diabetes Obes Metab

Ni J, Chen L, Su H, Cai J, Wang C, Lu W, Wang Y, Lu J, Xia T, Zhou J

doi: 10.1111/dom.70214

Atrial FibrillationThrombosis and Stroke

Atrial Fibrillation, Venous Thromboembolism, and Risk of Pulmonary Hypertension: A Swedish Nationwide Register Study

J Am Heart Assoc

Hjalmarsson C, Lindgren M, Bergh N, Hornestam B, Smith JG, Adiels M, Rosengren A

doi: 10.1161/JAHA.124.037418

Atrial Fibrillation

Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: a nationwide population study

Cardiovasc Diabetol

Ryu H, Lee SR, Choi EK, Go YH, Lee KY, Choi J, Han S, Kim JH, Ahn HJ, Kwon S, Kim BS, Han KD, Oh S, Lip GYH

doi: 10.1186/s12933-025-02795-5

Hypertension

Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)

Drugs Real World Outcomes

Escribano Subias P, Chakinala MM, Chin KM, Didden EM, Doad G, Farber HW, Gaine S, Hemnes AR, Highland KB, Lange TJ, McLaughlin V, Muller A, Rahman M, Remeňová T, Söderberg S, Venkatesh A, Kim NH

doi: 10.1007/s40801-025-00536-4

Atrial FibrillationFurther Publications

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

Circ Arrhythm Electrophysiol

Venier S, Defaye P, Lochon L, Benali R, Bisson A, Carabelli A, Diouf Y, Jacon P, Fauchier L

doi: 10.1161/CIRCEP.125.014101

Heart Failure

Prognosis After >50% Decline in eGFR in Heart Failure Patients: A Nationwide Real-World Study

JACC Heart Fail

Anjum DZ, Elmegaard M, Garred CH, Nouhravesh N, Fosbol E, Jhund PS, McMurray JJV, Petrie MC, Køber L, Schou M

doi: 10.1016/j.jchf.2025.02.027

Related content

Heart Failure and Stroke Risk in Atrial Fibrillation: Temporal Trends From a Nationwide Cohort Study

Atrial fibrillation recurrence and outcomes in patients with hypertrophic cardiomyopathy: Insights from a nationwide real-world cohort

Clinical Impact of Switching From or Persisting With Rivaroxaban or Apixaban After a Bleeding Event: A Real-World Study in Patients With Nonvalvular Atrial Fibrillation

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Atrial Fibrillation, Venous Thromboembolism, and Risk of Pulmonary Hypertension: A Swedish Nationwide Register Study

Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: a nationwide population study

Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies)

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis

Prognosis After >50% Decline in eGFR in Heart Failure Patients: A Nationwide Real-World Study